CA2671470C — Powder formulation for valganciclovir
Assigned to Cheplapharm Arzneimittel GmbH · Expires 2012-05-01 · 14y expired
What this patent protects
The present invention provides novel solid pharmaceutical dosage forms of valganciclovir hydrochloride for oral administration, after being constituted in water.These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus …
USPTO Abstract
The present invention provides novel solid pharmaceutical dosage forms of valganciclovir hydrochloride for oral administration, after being constituted in water.These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.